Verdict: Side-by-side breakdown using the Bull Rankings model. BNTX scored 28.0, INVA scored 76.1 — INVA leads.
Compare another set
BNTX
BioNTech SE
Biotechnology · Quality-Growth
28
$96.96 · $24.4B
fundamentals as of
Score gap
48.1
INVA leads
INVA
Innoviva, Inc.
Biotechnology · Quality-Growth
76.1
$21.21 · $1.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthINVA+18.8%
Strongest balance sheetBNTX0.02
Highest qualityINVA67 / 100
Largest discount to fair valueINVA-54%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BNTX
stronger →← stronger
INVA
35
Qualityreturns · margins · balance sheet
67
44
Growthrevenue & earnings expansion
71
17
Valuevaluation vs sector peers
92
INVA is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
BNTX
INVA
$499mC
FCF
$189mC
+4.3%C+
Rev
+18.8%B+
0.02A-
D/E
0.27B
8.2xC+
P/S
—
0.05A
PEG
3.12D
—
P/E
5.0xA
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BNTX
INVA
160% above
Price vs fair valuelower is cheaper
54% below
~41%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-11%/yr
-70%
1-yr DCF upside
+97%
-62%
5-yr DCF upside
+117%
-46%
10-yr DCF upside
+150%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BNTX
Why this score
Diluting shareholders
Foreign reporter (EUR)
INVA
Why this score
Diluting shareholders
The companies
BNTXBioNTech SE
Biotechnology · $96.96 · beta 1.25
Why now
Biotechnology · market cap $24.4b. Down 22% from 52-week high of $124.00 — deep drawdown territory. PEG 0.05 — paying under fair value for the growth rate. 20 sell-side analysts rate this a Buy with a mean 1-yr target of $116.21 (implying +20% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -63.6%) — path to GAAP profitability is the core thesis risk. ROE -9% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
INVAInnoviva, Inc.
Biotechnology · $21.21 · beta 0.38
Why now
Biotechnology · market cap $1.5b. 16% off the 52-week high of $25.15. Revenue growing +19%, comfortably above the S&P median. 5 sell-side analysts publish a mean 1-yr target of $35.00 (implying +65% upside).
Moat
Net margin 81% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BNTX and INVA diverge
On the headline score the gap is 48.1 points in favor of INVA. The widest single difference is Value, where INVA leads by 75.2 points.
ValueBNTX 16.7 · INVA 91.9INVA +75.2
QualityBNTX 35.0 · INVA 67.4INVA +32.4
GrowthBNTX 43.8 · INVA 71.2INVA +27.4
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is INVA or BNTX the better stock?
INVA scores higher: INVA 76.1, BNTX 28.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do INVA and BNTX differ most?
The widest gap is value, where INVA leads by 75 points on the 0–100 pillar scale. INVA leads all three pillars, so the gap is broad rather than a single-measure difference.
How are INVA and BNTX scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.